Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study.

Abstract

PURPOSE:

To determine the benefit of whole brain radiotherapy (WBRT) and the use of the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) classification system in patients with brain metastases from renal cell carcinoma.

METHODS AND MATERIALS:

We identified 46 consecutive patients with brain metastases from renal cell carcinoma who were treated with WBRT at the Cleveland Clinic Foundation between 1983 and 2000. We reviewed their charts for patient and tumor characteristics and categorized them according to the RTOG RPA classes.

RESULTS:

The median follow-up and survival time for all 46 patients (15 women and 31 men) was 3.0 months. The median radiation dose was 3000 cGy in 10 fractions. Patients who received higher radiation doses (>3000 cGy) survived longer than those who received 3000 cGy or less than 3000 cGy (8.5 months vs. 2.7 months vs. 0.4 months, p = 0.0289). However, the Karnofsky performance status and RPA class were confounding factors in these data. The median survival for patients by RTOG RPA class was 8.5 months for Class I (n = 2), 3 months for Class II (n = 37), and 0.6 months for Class III (n = 7, p = 0.0834).

CONCLUSION:

Despite the relatively poor prognosis of patients who receive WBRT alone, it appears that they benefit from this palliative treatment. The RTOG RPA classification system may be a useful tool in assessing prognosis in this patient population.

• Authors: Steven B Cannady, Kelly A Cavanaugh, Shih-Yuan Lee, Ronald M Bukowski, Thomas E Olencki, Glen H J Stevens, Gene H Barnett, John H Suh
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 58 Issue 1 Pg. 253-8 (Jan 01 2004) ISSN: 0360-3016 [Print] United States
• PMID: 14697446 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Adult
• Aged
• Aged, 80 and over
• Brain Neoplasms (radiotherapy, secondary)
• Carcinoma, Renal Cell (radiotherapy, secondary)
• Female
• Humans
• Karnofsky Performance Status
• Kidney Neoplasms (pathology)
• Male
• Middle Aged
• Palliative Care
• Radiotherapy Dosage
• Retrospective Studies